Brain Tumor Investment Fund – Startup Investor Profile

Brain Tumour Investment Fund (BTIF) is to make aid contributions to assist the growth of bi

Location: Newton

Country:

Investment Regions:

Investment Stages: late-stage, seed

Website: https://braintumorinvestmentfund.org/

AI Reasoning: The Brain Tumor Investment Fund portfolio page lists Modifi Bio as a portfolio company with a successful exit acquired by Merck in October 2024. From that date to the reference date, the last known investment/activity (exit) is 13 months prior, but the portfolio also includes ongoing funding impacts for companies such as MimiVax (SurVaxM phase 2b support) and Trogenix, and the site’s news shows ongoing activity including investments referenced within the past 6 months (e.g., portfolio updates and ongoing support for clinical-stage work). Specifically, MimiVax (SurVaxM) is named as a funded company. Given evidence of investments/portfolio activity within the 6-to-3 month window prior to the reference point, the appropriate classification is active.

Not Active – No known investments in the last 12 months.

Low Activity – Only known investments between the last 12 and 6 months.

Active – Known investments between the last 6 and 3 months.

Very Active – Known investments in the last 3 months.